Parpi

Summary

Parpi (CHEMBL4650351) is a phase-3 clinical-stage small molecule; indicated across 1 condition including head and neck cancer.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 4
• Chemistry: 488.5 Da · C27H22F2N4O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650351
Name	Parpi
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	130443213
Molecular formula	C27H22F2N4O3
Molecular weight	488.5
InChIKey	LTZZZXXIKHHTMO-UHFFFAOYSA-N

SMILES: C1CN(CCN1C(=O)C2=CC=C(C=C2)F)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F

IUPAC name: 4-[[4-fluoro-3-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]phenyl]methyl]-2H-phthalazin-1-one

Also known as: Parpi, PARPI

Patent coverage: 630 distinct patent families (1,217 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
head and neck cancer	1	MONDO:0005627	EFO:0006859

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04515602	PHASE3	NOT_YET_RECRUITING	Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
NCT03631017	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Imaging With a PET Agent for Detection of Cancers of the Head and Neck
NCT05826964	PHASE2	ACTIVE_NOT_RECRUITING	Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT06490380	Not specified	COMPLETED	HRD Status Reference Standard Based on WGS

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).